Theravance Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) said management will participate in two investor conferences in December 2025: a Fireside Chat at the Evercore Healthcare Conference on Dec 4, 2025, 8:20–8:40 AM ET in Coral Gables, FL (live webcast), and a Panel at the Oppenheimer Movers in Rare Disease Summit on Dec 11, 2025, 2:15–2:45 PM ET in New York. Theravance will be available for one-on-one meetings at both events. Interested investors should contact their representatives to request meetings. The Evercore webcast will be accessible on the company Events and Presentation investor page with a replay archived for 30 days.

News Market Reaction

-4.11%

1 alert

-4.11% News Effect

On the day this news was published, TBPH declined 4.11%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025:

8^th Annual Evercore Healthcare Conference
Location: Coral Gables, FL
Format: Fireside Chat
Date: Thursday, December 4, 2025
Time: 8:20-8:40 AM ET
Webcast

Oppenheimer Movers in Rare Disease Summit
Location: New York, NY
Format: Panel Discussion - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts
Date: Thursday, December 11, 2025
Time: 2:15-2:45 PM ET

Theravance will be available for one-on-one meetings during both events. Interested investors should contact their respective representatives to request meetings.

A live webcast of the Evercore presentation may also be accessed on the "Events and Presentation" page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-upcoming-investor-conferences-302619765.html

SOURCE Theravance Biopharma, Inc.

FAQ

When will Theravance Biopharma (TBPH) present at the Evercore Healthcare Conference in December 2025?

Theravance presents on Dec 4, 2025 from 8:20–8:40 AM ET in Coral Gables, FL; a live webcast will be available.

How can investors watch TBPH's Evercore presentation webcast?

The live webcast is on the company's Events and Presentation investor page and a replay will be archived for 30 days.

When and where will TBPH participate in the Oppenheimer Movers in Rare Disease Summit?

Theravance will join a panel on Dec 11, 2025 at 2:15–2:45 PM ET in New York for elevator-pitch style presentations.

Can investors request one-on-one meetings with TBPH management at these December 2025 events?

Yes; Theravance said management will be available for one-on-one meetings at both events and investors should contact their representatives to request meetings.

Will TBPH make presentation materials available after the events in December 2025?

The company stated the Evercore webcast replay will be archived for 30 days; presentation materials may be posted on the investor Events and Presentation page.

What topics will TBPH cover at the Rare Disease panel on Dec 11, 2025?

The panel format is described as elevator pitches from rare disease companies highlighting near-term, potentially stock-moving catalysts.